Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
The inspection closed with the facility receiving an inspection classification of NAI
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company
Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies.
The inspection concluded with no observations
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Subscribe To Our Newsletter & Stay Updated